Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives

Valentina Mengardo1 · Maria Bencivenga1 · Jacopo Weindelmayer1 · Michele Pavarana2 · Simone Giacopuzzi1 · Giovanni de Manzoni1

Received: 21 January 2018 / Accepted: 13 May 2018 / Published online: 30 May 2018
© Italian Society of Surgery (SIC) 2018

Abstract
Involvement of para-aortic nodes (PAN) has been detected at pathological examination in 10–25% of locally advanced gastric cancer. Based on these data of nodal diffusion, the lymphadenectomy of para-aortic stations would be desirable in locally advanced gastric cancer. However, the debate on the oncological benefit of para-aortic nodes dissection is still not solved. A review of the literature was performed and papers reporting either the rate of para-aortic nodal metastases or the long-term survival outcomes after D2+ para-aortic nodes dissection (PAND) or D3 lymphadenectomy were descriptively reported. The literature survey yielded 14 studies. Most of the papers show the outcome of series of advanced gastric cancer treated with surgery alone, while starting from 2012, 3 articles report the outcomes of D2+ PAND or D3 lymphadenectomy after preoperative chemotherapy. The rate of PAN metastases ranges between 8.5 and 28% in surgical series. Survival outcomes largely improved in series of patients treated with multimodal approach compared to those of surgery alone. In patients with clinically detected para-aortic nodal metastases, preoperative chemotherapy followed by PAND is indicated. More data are needed to clarify the indication to prophylactic PAND in the era of multimodal treatment, anyway super-extended lymphadenectomies have to be performed by experienced surgeons in dedicated centres.

Keywords Gastric cancer · Lymphadenectomy · Para-aortic lymphadenectomy

Introduction
Despite the declining incidence and the therapeutic improvements achieved in the last decades, gastric cancer (GC) is still a major cause of cancer death worldwide [1]. Therefore, further improvements in treatment through more tailored strategies are essential.

Surgery remains the cornerstone of curative intent therapy. As such, the extent of surgical resection, especially the extent of lymphadenectomy, is one of the key elements that needs to be personalized according to patients and tumours characteristics to get the best outcome for each patient by balancing post-operative complications and oncological benefits.

Involvement of para-aortic nodes (PAN) has been detected at pathological examination in 10–25% of locally advanced GCs [2, 3] when considering also the incidence of micrometastases, Natsugoe et al. reported a positivity rate up to 64% [4].

Based on the data of nodal diffusion, the lymphadenectomy of para-aortic stations would be desirable in locally advanced gastric cancer. However, the debate on the oncological benefit of para-aortic nodes dissection is still not solved. Indeed, on the other hand, para-aortic nodal involvement is considered as expression of a metastatic disease both by the 8th edition of TNM staging [5] and the 3rd Japanese Classification of gastric cancer [6], while on the other hand some authors [7], suggest considering the cases of gastric cancer harbouring metastases to the para-aortic nodes as borderline resectable rather than metastatic tumours as the long-term outcomes observed in such patients are much more better compared with other metastatic tumours [8].

In the present review, based on the available literature data,
we will describe the current indications to para-aortic nodal dissection as well as the open questions on this topic.

Methods

VM searched PubMed for papers using the key words “para-aortic” AND “gastric cancer” AND “lymphadenectomy”. Only studies in English language reporting either the rate of para-aortic nodal metastases or the long-term survival outcomes after D2+ PAND or D3 lymphadenectomy were included. Results of literature review were descriptively reported.

Results

The literature survey yielded 14 studies [9] (Table 1). Most of the papers show the outcome of series of advanced gastric cancer treated with surgery alone [9], while starting from 2012, 3 articles report the outcomes of D2+ para-aortic or D3 lymphadenectomy after preoperative chemotherapy [20]. The rate of PAN metastases ranges between 8.5 and 26.1% in surgical series where no selection of patients based on tumour site was made [11]. The rate of PAN metastases was 28% in a surgical series including only upper third tumours [9]. Survival outcomes largely improved in series of patients treated with multimodal approach compared to those with surgery alone (Table 1).

Discussion

History of para-aortic nodal dissection in gastric cancer

D2 lymphadenectomy is the standard of care in Japan and South Korea since decades [23, 24], more recently also in Europe the guidelines recommend the extended D2 dissection in case of curative intent treatment of GC [25–28]. The benefit of further extending the lymphadenectomy beyond the D2 is controversial.

Table 1 Main studies (in English language) that reported data on para-aortic nodes dissection, involvement rate and long-term outcomes in patients with pathological positivity of PAN (pPAN+) after super-extended dissection

<table>
<thead>
<tr>
<th>Author/year</th>
<th>N patients underwent D2+ PAND or D3 lymphadenectomy</th>
<th>% neoadjuvant</th>
<th>% pathologically positive PAN</th>
<th>5-year OS of all D2+ PAND/cohort, (%)</th>
<th>5-year OS of pPAN+ patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baba et al. 2000 [9]</td>
<td>75c</td>
<td>0</td>
<td>28</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kunisaki et al. 2006 [10]</td>
<td>150</td>
<td>0</td>
<td>NA</td>
<td>54</td>
<td>–</td>
</tr>
<tr>
<td>Sasako et al. 2008 [11]</td>
<td>260d</td>
<td>0</td>
<td>8.5</td>
<td>54.9</td>
<td>18.5%</td>
</tr>
<tr>
<td>Yonemura et al. 2008 [12]</td>
<td>134</td>
<td>0</td>
<td>9.0</td>
<td>55</td>
<td>25%</td>
</tr>
<tr>
<td>Fujimura et al. 2009 [13]</td>
<td>222</td>
<td>0</td>
<td>24.7</td>
<td>–</td>
<td>22%</td>
</tr>
<tr>
<td>Roviello et al. 2010 [14]</td>
<td>286</td>
<td>0</td>
<td>12.9</td>
<td>52</td>
<td>17%</td>
</tr>
<tr>
<td>Tokunaga et al. 2010 [15]</td>
<td>178e</td>
<td>0</td>
<td>100</td>
<td>–</td>
<td>13–28.6% if ≤15 positive nodes, no macroscopic type 4</td>
</tr>
<tr>
<td>De Manzoni et al. 2015 [16]</td>
<td>294</td>
<td>0</td>
<td>11.6</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Marrelli et al. 2017 [18]</td>
<td>390</td>
<td>0</td>
<td>10.8</td>
<td>–</td>
<td>11 ± 5%a</td>
</tr>
<tr>
<td>Kumagai et al. 2017 [19]</td>
<td>23 (16 a2)b</td>
<td>NA</td>
<td>25 (16 a2)</td>
<td>–</td>
<td>50.0% (16 a2)</td>
</tr>
<tr>
<td></td>
<td>20 (16 b1)b</td>
<td>26.1 (16 b1)</td>
<td>–</td>
<td>40.0% (16 b1)</td>
<td></td>
</tr>
<tr>
<td>Oyama et al. 2012 [20]</td>
<td>44c</td>
<td>36</td>
<td>100</td>
<td>–</td>
<td>32.9% (no preop CT)NB</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>93.8% (after preop CT)NB</td>
<td></td>
</tr>
<tr>
<td>Tsuburaya et al. 2014 [21]</td>
<td>51</td>
<td>100</td>
<td>–</td>
<td>53</td>
<td>57% (if no bulky N2)</td>
</tr>
<tr>
<td>Fujiwara et al. 2015 [22]</td>
<td>20f</td>
<td>100</td>
<td>40</td>
<td>65</td>
<td>–</td>
</tr>
</tbody>
</table>

aThe survival is reported as cancer-related 5-year survival probability (± standard error)
bOnly tumours with duodenal invasion
cOnly upper third tumours
dOnly prophylactic PAND
eOnly patients with pathologically positive para-aortic nodes
fOnly patients with clinically positive para-aortic lymph nodes
NB2-year OS

Springer
The para-aortic area is considered as the outmost nodal station before the systemic lymphatic flow. Based on this consideration and according to retrospective data reporting a high rate (10–30%) of PAN pathological involvement [29], D2+ para-aortic nodal dissection (PAND) or super-extended D3 lymphadenectomy have been routinely performed for advanced gastric cancer in Japan as well as in dedicated Western centres in the past decades.

Both Eastern and European authors reported satisfying long-term outcomes in patients with pathological positivity of PAN (pPAN+) after super-extended dissection (Table 1). Tokunaga et al. showed that in pPAN+ patients, if excluding cases with linitis plastica or with more than 15 positive lymph nodes, 5-year overall survival was 28.6% after D3 dissection [15]. Similarly, in a study of the Italian Research Group for Gastric Cancer (GIRCG), the 5-year overall survival in pPAN+ after D3 lymphadenectomy was 17% [30].

However, since the publication of the Japan Clinical Oncology Group (JCOG) 9501 trial [11], showing no survival benefit of prophylactic D2+ PAND compared to D2 lymphadenectomy alone in advanced gastric cancer, the routine PAND is no more indicated.

Of note, that trial excluded cases with clinically detected PAN metastases, leading to a lower rate of PAN metastases retrieved at pathological examination (8.5%) compared to previous studies. Nevertheless, Sasako et al. reported a not negligible 5-year overall survival rate of 18.2% in patients with PAN metastases after prophylactic PAN dissection. Moreover, that trial [11], although not finding any significant survival advantage after PAN dissection with respect to simple D2 in the whole sample, highlighted significant interactions between T or N status and extension of lymphadenectomy (p = 0.004 and p = 0.003, respectively): paradoxically, patients with less advanced cancer (subserosal and node-negative tumours) showed a significant benefit from PAN dissection.

Taken together, these considerations suggest the possibility that the D2+ PAND can offer a chance of cure in selected patients with advanced GC without clinically detectable PAN metastases [31].

All the above-mentioned evidences suggest the need of further investigations on the role of PAN dissection in advanced GC, especially if considering the increasing efficacy of chemotherapy regimens either in neo-adjuvant or in metastatic setting.

Both, the role of PAND in patients with clinically positive PAN and the role of prophylactic PAND should be reconsidered in the era of multimodal treatment.

**Para-aortic nodal dissection in the era of multimodal treatment**

Interesting findings arise from recent studies exploring the role of para-aortic dissection after preoperative chemotherapy [20–22] (Table 1). A phase II Japanese trial demonstrated that in patients with clinically detected extensive nodal metastases (bulky nodes in the D2 stations) with or without lymphadenopathy in the para-aortic (No. 16 a2–b1) regions, a multidisciplinary treatment including two courses of neo-adjuvant chemotherapy with S-1+ cisplatin followed by D2 plus PAND lead to a 5-year survival rate of 53% [21].

Specifically, in patients with clinically bulky nodes in the second-level perigastric stations without preoperative evidence of PAN metastases, the 5-year overall survival was 68%, while in patients with clinically detected PAN metastases without bulky N2 nodes, the 5-year overall survival was 57%, while in patients with both initial bulky N2 and PAN metastases the 5-year overall survival was 17%.

Interestingly, only 15 (31%) of patients included in the trial were pathologically staged as pN3, including PAN metastases: according to the clinical node status in 48 eligible patients who underwent surgery, pN3 disease was found in 5 of 24 patients with bulky N2 disease only, 4 of 14 with bulky PAN involvement alone, and 5 of 10 with both bulky N2 and PAN-positive tumours.

Of note, in that trial, peritoneal metastasis as well as the peritoneal cytology status had to be ruled out by staging laparoscopy prior to registration. The results of this Japanese trial are very relevant and confirm that in the era of multimodal treatment the role of PAN dissection is beneficial in patients with clinically detected PAN metastases after chemotherapy unless peritoneal cytology or peritoneal metastases are detected at staging laparoscopy. But also a role of “prophylactic” PAND after preoperative chemotherapy in locally advanced gastric cancer is suggested. In this case, the prophylactic PAND after chemotherapy was demonstrated highly beneficial (5-year OS 68%) in patients with bulky N2, i.e., one node ≥ 3 cm or two adjacent nodes ≥ 1.5 cm in the second-level perigastric stations. Moreover, also other patients with locally advanced gastric cancer may benefit from the prophylactic extension of lymphadenectomy to the para-aortic area. Indeed, a recent Korean study, by analysing 2618 patients who had undergone gastrectomy with D2 lymphadenectomy for gastric cancer very rarely (1.3% of cases) extended to PAN [32], reported a loco-regional relapse rate of 8.5% 5 years after surgery, this was most often seen outside the D2 dissected area (90.4%) in particular in the stations 16 a2 and 16 b1 (46 and 60%, respectively). These findings further support the hypothesis that some subgroups of patients with advanced gastric cancer have PAN micrometastases or metastases that are not detectable through the current available preoperative imaging examinations. It could be hypothesized that prophylactic PAND would prevent loco-regional relapse in these patients, especially if there is a good clinical response to preoperative chemotherapy.
**How to select patients for prophylactic PAND in the era of multimodal treatment?**

Based on the consideration that patients with clinically detectable PAN metastases treated with preoperative chemotherapy followed by PAND have a good prognosis [21], the same treatment option should not be denied to those patients who have clinically negative but pathological positive PAN. Indeed, even if a good accuracy of CT scan has been reported both by Eastern and Western authors [33, 34] in some cases of locally advanced gastric cancer with diffuse histotype, pathological nodal metastases were found also in clinically negative cases. Moreover, as stated above, the possible role of PAND on preventing cancer relapse by blocking lymphatic channels from the stomach or removing PAN micrometastases, is basically unknown.

Of course, the problem is how to identify the patients with locally advanced gastric cancer at high risk of PAN metastases [18] that may benefit from PAND.

Interestingly, in a previous study by our group, by analysing a series of patients with advanced gastric cancer including those with PAN metastases, we found that the rate of loco-regional relapse was comparable after D2 or D3 lymphadenectomy (16.4% vs. 17%) in the whole series. However, we found a significantly higher risk of loco-regional recurrence in the diffuse histotype after D2 compared with D3 [16]. It is likely that a more extended lymphadenectomy had played a better local control of those tumours that have a higher lymphotropism, and both patients with clinical positive PAN and those with pathological positive, but clinical negative PAN or with PAN micrometastasis could have benefit from D3.

Considering the high proportion of Laurèn diffuse type especially of signet ring cell tumours that is currently observed in the West [35], the benefit of prophylactic PAND need to be evaluated through a dedicated trial comparing D2 versus D2+ PAND or D3 in tumours with Laurèn diffuse/WHO poorly cohesive and SRC tumours after neo-adjuvant chemotherapy.

Of course, the possible oncological benefit of super-extended lymphadenectomy should be balanced with the risk of post-operative complications and mortality. Therefore, super-extended lymphadenectomies should be performed in dedicated high-volume hospitals.

**Conclusion**

In patients with clinically detected para-aortic nodal metastases, preoperative chemotherapy followed by PAND is indicated. Prophylactic PAND after neo-adjuvant treatment could also be of benefit in some subgroups of locally advanced gastric cancer at high risk of PAN metastases such as cases with bulky nodes in the second level perigastric nodal stations or with Laurèn diffuse/WHO poorly cohesive and SRC tumours. More data are needed to clarify the indication TP prophylactic PAND, anyway super-extended lymphadenectomies have to be performed by experienced surgeons in dedicated centres.

**Sources of financial support** None.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Research involving human participants and/or animals** The research does not involve Human Participants and/or Animals.

**Informed consent** There was no need to get informed consent.

**References**


